📌 Archived version v1.2 (2026-05-31) — a fixed snapshot for citation. View current version →

SQ-LIP-000008 · v1.2 (archived) · View current version →

Is lipedema associated with fibromyalgia and other chronic-pain conditions?

ComorbiditiesPain
Current answer

Based on currently indexed evidence, lipedema is consistently associated with chronic pain and frequently co-occurs with fibromyalgia. Multiple cross-sectional studies using ACR 2016 diagnostic criteria report fibromyalgia prevalence of approximately 34–35% among women with lipedema (DOI:10.1089/lrb.2023.0038; DOI:10.2147/jpr.s315736), while an earlier study found lipedema in 50% of women already meeting fibromyalgia criteria (DOI:10.1177/02683555251321042). Pain burden in lipedema is substantial: 100% of lipedema patients in one controlled study reported pain versus 70.8% of matched controls, with 43.2% reporting severe pain-related disability versus 9.2% of controls (DOI:10.3390/life14030295). In a large cohort of 860 patients, 99% had at least one comorbidity, with joint pain in 58%, migraine in 35%, and insomnia in 36%, though fibromyalgia was not separately enumerated (DOI:10.1111/ddg.15064). Phenotypic overlap between lipedema and fibromyalgia includes diffuse soft-tissue pain, allodynia, and correlated pain-depression scores (rho≈0.61), though fibromyalgia showed worse scores across all SF-36 domains. Fatigue (~75%), hypermobility (>50%), and psychosocial distress are additional chronic-pain-related features of lipedema. All data are observational and largely cross-sectional; causal direction and whether shared mechanisms underlie the co-occurrence remain unestablished.

Knowledge stateEmerging
Knowledge freshness88% recent · current evidence base
Last updated2026-05-31
Human reviewnot yet reviewed
4supporting
0contradicting
3refining / context

Knowledge freshness = share of the 8 indexed evidence sources from the last 5 years (newest 2025, oldest 2018) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

20182025Lipedema: friend and foe — Torre et al. (2018) · contextPotential Effects of a Modified Mediterranean Diet on Body Composition in Lipoedema — Di Renzo et al. (2021) · contextCommon and Contrasting Characteristics of the Chronic Soft-Tissue Pain Conditions Fibromyalgia and Lipedema — Angst et al. (2021) · supportingPrevalência e fatores de risco para lipedema no Brasil — Amato et al. (2022) · supportingBreaking the circle‐effectiveness of liposuction in lipedema — Seefeldt et al. (2023) · contextPrevalence of Fibromyalgia Syndrome in Women with Lipedema and Its Effect on Anxiety, Depression, and Quality of Life — Cagliyan Turk et al. (2024) · supportingHealth Implications of Lipedema: Analysis of Patient Questionnaires and Population-Based Matched Controls — Kempa et al. (2024) · supportingLipedema awareness in fibromyalgia — Bolkan Günaydın et al. (2025) · supporting

supporting   contradicting   refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.

How to cite this version

    
    

Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.

What changed in this version

This update added multiple cross-sectional studies with validated diagnostic criteria that quantified fibromyalgia comorbidity at 34–35% in lipedema populations, documented that 100% of lipedema patients report pain versus matched controls, and provided large-cohort comorbidity data, substantially strengthening and numerically grounding the previously approximate estimate of 'about half' and clarifying that the earlier figure likely reflected a fibromyalgia-enriched sample.

Supporting claims

Contradictory claims

Refining / context

Major uncertainty

The direction of causality between lipedema and fibromyalgia is unknown. It is unclear whether shared pathophysiological mechanisms (e.g., central sensitization, connective tissue abnormalities, hormonal factors) underlie the co-occurrence, or whether ascertainment bias inflates estimates due to overlapping symptom criteria. Most data rely on self-report or single-center samples, and prospective or mechanistic studies are absent.

Version history

Key references

DOI:10.1177/02683555251321042 · DOI:10.1590/1677-5449.202101981 · DOI:10.3390/nu13020358 · DOI:10.1089/lrb.2023.0038 · DOI:10.2147/jpr.s315736 · DOI:10.3390/life14030295 · DOI:10.1111/ddg.15064 · DOI:10.1515/hmbci-2017-0076